Industries > Pharma > Top 30 Oncology Drugs Manufacturers 2019

Top 30 Oncology Drugs Manufacturers 2019

AstraZeneca, Merck, Novartis, Amgen, GlaxoSmithKline, Johnson & Johnson, Roche, Pfizer, Eli Lilly, Other Companies

PUBLISHED: 03 May 2019
PAGES: 157
PRODUCT CODE: PHA0417
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0417 Categories: , Tags: , , , , ,

Cancer treating drugs market forms the most lucrative sector in pharmaceuticals. As the ageing population continues to rise across the world, the incidence of cancer will continue to grow, leading to increased spending on cancer-treating medicines. This report lists and discusses the top 30 oncology drugs manufacturers.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 157-page report you will receive 83 tables and 64 figures–all unavailable elsewhere.

The 157-page report provides clear detailed insight into the top 30 oncology drugs manufacturers. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Assessment of the leading companies in the global oncology drugs market. The list below shows some of the companies that are discussed in the report:
• Abbott Laboratories
• AbbVie
• Amgen
• Astellas Pharma
• AstraZeneca
• Aurora Biophama
• Boehringer Ingelheim
• Bristol-Myers Squibb (BMS)
• Celgene Corporation
• Eli Lilly
• Fresenius Kabi
• Gilead
• GlaxoSmithKline (GSK)
• Grifols
• Johnson & Johnson
• Jounce Therapeutics
• Other companies

Top 30 Oncology Drugs Manufacturers 2019

• For each company, the report provides information and discussion on:
• Company overview
• Product portfolio
• Recent development
• Financial information

• Key questions answered by this report:
• How is the Oncology Drugs Manufacturers market evolving?
• What is driving and restraining the Oncology Drugs Manufacturers market?
• What will be the main driver for the overall market?
• Will leading Oncology Drugs Manufacturers broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?

Visiongain’s study is intended for anyone requiring commercial analyses for the Top 30 Oncology Drugs Manufacturers 2019. You find data, trends and predictions.

Buy our report today Top 30 Oncology Drugs Manufacturers 2019: AstraZeneca, Merck, Novartis, Amgen, GlaxoSmithKline, Johnson & Johnson, Roche, Pfizer, Eli Lilly, Other Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Top 30 Oncology Drugs Manufacturers 2019


Download sample pages

Complete the form below to download your free sample pages for Top 30 Oncology Drugs Manufacturers 2019


Latest Pharma news

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

READ

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

READ

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

READ

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

READ

Categories

Category